Zura Bio Limited (ZURA)
NASDAQ: ZURA · IEX Real-Time Price · USD
3.490
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
3.440
-0.050 (-1.43%)
Pre-market: Jul 22, 2024, 6:12 AM EDT
Company Description
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.
It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
The company is based in Henderson, Nevada.
Zura Bio Limited
| Country | United States |
| Founded | 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Robert Lisicki |
Contact Details
Address: 4225 Executive Square, Suite 600 La Jolla, California 92037 United States | |
| Phone | 858-247-0520 |
| Website | zurabio.com |
Stock Details
| Ticker Symbol | ZURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001855644 |
| ISIN Number | KYG9TY5A1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert Lisicki | President, Chief Executive Officer and Chief Operating Officer |
| Dr. Someit Sidhu M.D. | Founder and Non-Independent Director |
| Verender S. Badial | Chief Financial Officer |
| Dr. Michael D. Howell Ph.D. | Chief Scientific Officer |
| Kimberly Ann Davis | Chief Legal Officer and Secretary |
| Dr. Gary Whale Ph.D. | Chief Technology Officer |
| Theresa Lowry | Chief Human Resources Officer |
| David Brady | Head of Business Development |
| Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer and Head of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 12, 2024 | 425 | Filing |
| Jul 12, 2024 | 8-K | Current Report |
| Jul 12, 2024 | SC TO-I | Filing |
| Jul 12, 2024 | S-4 | Filing |
| Jul 2, 2024 | 8-K/A | [Amend] Current report |
| Jun 18, 2024 | EFFECT | Notice of Effectiveness |
| Jun 18, 2024 | POS AM | Post-Effective amendments for registration statement |
| Jun 14, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 8-K | Current Report |
| Jun 4, 2024 | 424B3 | Prospectus |